The impact of Organic Anion-Transporting Polypeptides (OATPs) on disposition and toxicity of antitumor drugs: Insights from knockout and humanized mice

Drug Resistance Updates

Volumn 27, Issue , 2016, Pages 72-88

  Durmus, Selvi ^a   van Hoppe, Stéphanie ^b   Schinkel, Alfred H ^b  

^a BILKENT UNIVERSITY   (Turkey)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Drug disposition; Drug drug interactions; Hepatic uptake; OATP1A 1B transporters; OATP1B1; OATP1B3

Indexed keywords

ANTINEOPLASTIC AGENT; BILIRUBIN; BILIRUBIN GLUCURONIDE; CABAZITAXEL; CARBOPLATIN; CARBOXYLESTERASE; CISPLATIN; DOCETAXEL; DOXORUBICIN; FIRTECAN; GLUCURONIDE; HEME; IRINOTECAN; METHOTREXATE; ORGANIC ANION TRANSPORTER; OXALIPLATIN; PACLITAXEL; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RIFAMPICIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1A; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B3; SORAFENIB; TAXANE DERIVATIVE; TELMISARTAN; UNCLASSIFIED DRUG; CAMPTOTHECIN; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; OATP1A1 PROTEIN, MOUSE; ORGANIC CATION TRANSPORTER; PLATINUM DERIVATIVE; SLCO1B1 PROTEIN, HUMAN; TAXOID;

ARTICLE; CLINICAL ASSESSMENT; DNA MODIFICATION; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DETOXIFICATION; DRUG DISPOSITION; DRUG EFFICACY; DRUG MECHANISM; DRUG TRANSPORT; GENETICALLY ENGINEERED MOUSE STRAIN; HEPATIC CLEARANCE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; LIVER CELL; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; THERAPY EFFECT; TRANSGENIC MOUSE; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; DEFICIENCY; DRUG EFFECTS; DRUG INACTIVATION; DRUG INTERACTION; GENE EXPRESSION; GENETICS; LIVER; METABOLISM; MOUSE; NEOPLASM; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DOXORUBICIN; DRUG INTERACTIONS; GENE EXPRESSION; HEPATOCYTES; HUMANS; INACTIVATION, METABOLIC; LIVER; METHOTREXATE; MICE; MICE, TRANSGENIC; NEOPLASMS; NIACINAMIDE; ORGANIC CATION TRANSPORT PROTEINS; PHENYLUREA COMPOUNDS; PLATINUM COMPOUNDS; SOLUTE CARRIER ORGANIC ANION TRANSPORTER FAMILY MEMBER 1B1; TAXOIDS;

EID: 84977150766     PISSN: 13687646     EISSN: 15322084     Source Type: Journal    
DOI: 10.1016/j.drup.2016.06.005     Document Type: Article

References (106)

1. Abe, T., Unno, M., Onogawa, T., Tokui, T., Kondo, T.N., Nakagomi, R., Adachi, H., Fujiwara, K., Okabe, M., Suzuki, T., Nunoki, K., Sato, E., Kakyo, M., Nishio, T., Sugita, J., Asano, N., Tanemoto, M., Seki, M., Date, F., Ono, K., Kondo, Y., Shiiba, K., Suzuki, M., Ohtani, H., Shimosegawa, T., Iinuma, K., Nagura, H., Ito, S., Matsuno, S., LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 120 (2001), 1689–1699.
2. Aller, S.G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P.M., Trinh, Y.T., Zhang, Q., Urbatsch, I.L., Chang, G., Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323 (2009), 1718–1722.
3. Assaraf, Y.G., Molecular basis of antifolate resistance. Cancer Metastasis Rev. 26 (2007), 153–181.
4. Badagnani, I., Castro, R.A., Taylor, T.R., Brett, C.M., Huang, C.C., Stryke, D., Kawamoto, M., Johns, S.J., Ferrin, T.E., Carlson, E.J., Burchard, E.G., Giacomini, K.M., Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J. Pharmacol. Exp. Ther. 318 (2006), 521–529.
5. Baker, S.D., Verweij, J., Cusatis, G.A., van Schaik, R.H., Marsh, S., Orwick, S.J., Franke, R.M., Hu, S., Schuetz, E.G., Lamba, V., Messersmith, W.A., Wolff, A.C., Carducci, M.A., Sparreboom, A., Pharmacogenetic pathway analysis of docetaxel elimination. Clin. Pharmacol. Ther. 85 (2009), 155–163.
6. Bakos, E., Evers, R., Sinko, E., Varadi, A., Borst, P., Sarkadi, B., Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol. Pharmacol. 57 (2000), 760–768.
7. Bram, E.E., Adar, Y., Mesika, N., Sabisz, M., Skladanowski, A., Assaraf, Y.G., Structural determinants of imidazoacridinones facilitating antitumor activity are crucial for substrate recognition by ABCG2. Mol. Pharmacol. 75 (2009), 1149–1159.
8. Cheng, X., Maher, J., Chen, C., Klaassen, C.D., Tissue distribution and ontogeny of mouse organic anion transporting polypeptides (Oatps). Drug Metab. Dispos. 33 (2005), 1062–1073.
9. Cortes-Funes, H., Coronado, C., Role of anthracyclines in the era of targeted therapy. Cardiovasc. Toxicol. 7 (2007), 56–60.
10. Cui, Y., Konig, J., Nies, A.T., Pfannschmidt, M., Hergt, M., Franke, W.W., Alt, W., Moll, R., Keppler, D., Detection of the human organic anion transporters SLC21A6 (OATP2) and SLC21A8 (OATP8) in liver and hepatocellular carcinoma. Lab. Invest. 83 (2003), 527–538.
11. de Graan, A.J., Lancaster, C.S., Obaidat, A., Hagenbuch, B., Elens, L., Friberg, L.E., de Bruijn, P., Hu, S., Gibson, A.A., Bruun, G.H., Corydon, T.J., Mikkelsen, T.S., Walker, A.L., Du, G., Loos, W.J., van Schaik, R.H., Baker, S.D., Mathijssen, R.H., Sparreboom, A., Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin. Cancer Res. 18 (2012), 4433–4440.
12. Drozdzik, M., Groer, C., Penski, J., Lapczuk, J., Ostrowski, M., Lai, Y., Prasad, B., Unadkat, J.D., Siegmund, W., Oswald, S., Protein abundance of clinically relevant multidrug transporters along the entire length of the human intestine. Mol. Pharm. 11 (2014), 3547–3555.
13. Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., Lydon, N.B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., Sawyers, C.L., Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344 (2001), 1031–1037.
14. Duran, G.E., Wang, Y.C., Francisco, E.B., Rose, J.C., Martinez, F.J., Coller, J., Brassard, D., Vrignaud, P., Sikic, B.I., Mechanisms of resistance to cabazitaxel. Mol. Cancer Ther. 14 (2015), 193–201.
15. Durmus, S., Lozano-Mena, G., van Esch, A., Wagenaar, E., van Tellingen, O., Schinkel, A.H., Preclinical mouse models to study human OATP1B1- and OATP1B3-mediated drug–drug interactions in vivo. Mol. Pharm. 12 (2015), 4259–4269.
16. Durmus, S., Naik, J., Buil, L., Wagenaar, E., van Tellingen, O., Schinkel, A.H., In vivo disposition of doxorubicin is affected by mouse Oatp1a/1b and human OATP1A/1B transporters. Int. J. Cancer. 135 (2014), 1700–1710.
17. Ekroos, M., Sjogren, T., Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 13682–13687.
18. Figg, W.D. 2nd, Figg, W.D., Cabazitaxel: filling one of the gaps in the treatment of prostate cancer. Cancer Biol. Ther. 10 (2010), 1233–1234.
19. Franke, R.M., Scherkenbach, L.A., Sparreboom, A., Pharmacogenetics of the organic anion transporting polypeptide 1A2. Pharmacogenomics 10 (2009), 339–344.
20. Gao, B., Hagenbuch, B., Kullak-Ublick, G.A., Benke, D., Aguzzi, A., Meier, P.J., Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J. Pharmacol. Exp. Ther. 294 (2000), 73–79.
21. Gewirtz, D.A., A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 57 (1999), 727–741.
22. Glaeser, H., Bailey, D.G., Dresser, G.K., Gregor, J.C., Schwarz, U.I., McGrath, J.S., Jolicoeur, E., Lee, W., Leake, B.F., Tirona, R.G., Kim, R.B., Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin. Pharmacol. Ther. 81 (2007), 362–370.
23. Gligorov, J., Lotz, J.P., Preclinical pharmacology of the taxanes: implications of the differences. Oncologist 9:Suppl. 2 (2004), 3–8.
24. Gonen, N., Assaraf, Y.G., Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist. Updat. 15 (2012), 183–210.
25. Gong, I.Y., Kim, R.B., Impact of genetic variation in OATP transporters to drug disposition and response. Drug Metab. Pharmacokinet. 28 (2013), 4–18.
26. Gong, L., Aranibar, N., Han, Y.H., Zhang, Y., Lecureux, L., Bhaskaran, V., Khandelwal, P., Klaassen, C.D., Lehman-McKeeman, L.D., Characterization of organic anion-transporting polypeptide (Oatp) 1a1 and 1a4 null mice reveals altered transport function and urinary metabolomic profiles. Toxicol. Sci. 122 (2011), 587–597.
27. Grenier, M.A., Lipshultz, S.E., Epidemiology of anthracycline cardiotoxicity in children and adults. Semin. Oncol. 25 (1998), 72–85.
28. Gui, C., Miao, Y., Thompson, L., Wahlgren, B., Mock, M., Stieger, B., Hagenbuch, B., Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur. J. Pharmacol. 584 (2008), 57–65.
29. Han, J.Y., Lim, H.S., Shin, E.S., Yoo, Y.K., Park, Y.H., Lee, J.E., Kim, H.T., Lee, J.S., Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. Lung Cancer 59 (2008), 69–75.
30. Harlow, G.R., Halpert, J.R., Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics. Proc. Natl. Acad. Sci. U. S. A. 95 (1998), 6636–6641.
31. Higgins, J.W., Bao, J.Q., Ke, A.B., Manro, J.R., Fallon, J.K., Smith, P.C., Zamek-Gliszczynski, M.J., Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein. Drug Metab. Dispos. 42 (2014), 182–192.
32. Hilger, R.A., Richly, H., Grubert, M., Kredtke, S., Thyssen, D., Eberhardt, W., Hense, J., Schuler, M., Scheulen, M.E., Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis. Int. J. Clin. Pharmacol. Ther. 47 (2009), 61–64.
33. Holmes, R.S., Wright, M.W., Laulederkind, S.J., Cox, L.A., Hosokawa, M., Imai, T., Ishibashi, S., Lehner, R., Miyazaki, M., Perkins, E.J., Potter, P.M., Redinbo, M.R., Robert, J., Satoh, T., Yamashita, T., Yan, B., Yokoi, T., Zechner, R., Maltais, L.J., Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins. Mamm. Genome 21 (2010), 427–441.
34. Hu, S., Franke, R.M., Filipski, K.K., Hu, C., Orwick, S.J., de Bruijn, E.A., Burger, H., Baker, S.D., Sparreboom, A., Interaction of imatinib with human organic ion carriers. Clin. Cancer Res. 14 (2008), 3141–3148.
35. Hu, S., Mathijssen, R.H., de Bruijn, P., Baker, S.D., Sparreboom, A., Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations. Br. J. Cancer 110 (2014), 894–898.
36. Huisman, M.T., Smit, J.W., Crommentuyn, K.M., Zelcer, N., Wiltshire, H.R., Beijnen, J.H., Schinkel, A.H., Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 16 (2002), 2295–2301.
37. Innocenti, F., Kroetz, D.L., Schuetz, E., Dolan, M.E., Ramirez, J., Relling, M., Chen, P., Das, S., Rosner, G.L., Ratain, M.J., Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J. Clin. Oncol. 27 (2009), 2604–2614.
38. Iusuf, D., Hendrikx, J.J., van Esch, A., van de Steeg, E., Wagenaar, E., Rosing, H., Beijnen, J.H., Schinkel, A.H., Human OATP1B1, OATP1B3 and OATP1A2 can mediate the in vivo uptake and clearance of docetaxel. Int. J. Cancer 136 (2015), 225–233.
39. Iusuf, D., Ludwig, M., Elbatsh, A., van Esch, A., van de Steeg, E., Wagenaar, E., van der Valk, M., Lin, F., van Tellingen, O., Schinkel, A.H., OATP1A/1B transporters affect irinotecan and SN-38 pharmacokinetics and carboxylesterase expression in knockout and humanized transgenic mice. Mol. Cancer Ther. 13 (2014), 492–503.
40. Iusuf, D., Sparidans, R.W., van Esch, A., Hobbs, M., Kenworthy, K.E., van de Steeg, E., Wagenaar, E., Beijnen, J.H., Schinkel, A.H., Organic anion-transporting polypeptides 1a/1b control the hepatic uptake of pravastatin in mice. Mol. Pharm. 9 (2012), 2497–2504.
41. Iusuf, D., van de Steeg, E., Schinkel, A.H., Functions of OATP1A and 1B transporters in vivo: insights from mouse models. Trends Pharmacol. Sci. 33 (2012), 100–108.
42. Iusuf, D., van de Steeg, E., Schinkel, A.H., Hepatocyte hopping of OATP1B substrates contributes to efficient hepatic detoxification. Clin. Pharmacol. Ther. 92 (2012), 559–562.
43. Iusuf, D., van Esch, A., Hobbs, M., Taylor, M., Kenworthy, K.E., van de Steeg, E., Wagenaar, E., Schinkel, A.H., Murine Oatp1a/1b uptake transporters control rosuvastatin systemic exposure without affecting its apparent liver exposure. Mol. Pharmacol. 83 (2013), 919–929.
44. Jain, L., Woo, S., Gardner, E.R., Dahut, W.L., Kohn, E.C., Kummar, S., Mould, D.R., Giaccone, G., Yarchoan, R., Venitz, J., Figg, W.D., Population pharmacokinetic analysis of sorafenib in patients with solid tumours. Br. J. Clin. Pharmacol. 72 (2011), 294–305.
45. Kathawala, R.J., Wang, Y.J., Shukla, S., Zhang, Y.K., Alqahtani, S., Kaddoumi, A., Ambudkar, S.V., Ashby, C.R. Jr., Chen, Z.S., ATP-binding cassette subfamily B member 1 (ABCB1) and subfamily C member 10 (ABCC10) are not primary resistance factors for cabazitaxel. Chin. J. Cancer 34 (2015), 115–120.
46. Kondratov, R.V., Komarov, P.G., Becker, Y., Ewenson, A., Gudkov, A.V., Small molecules that dramatically alter multidrug resistance phenotype by modulating the substrate specificity of P-glycoprotein. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 14078–14083.
47. Konig, J., Muller, F., Fromm, M.F., Transporters and drug–drug interactions: important determinants of drug disposition and effects. Pharmacol. Rev. 65 (2013), 944–966.
48. Koolen, S.L., Beijnen, J.H., Schellens, J.H., Intravenous-to-oral switch in anticancer chemotherapy: a focus on docetaxel and paclitaxel. Clin. Pharmacol. Ther. 87 (2010), 126–129.
49. Lagas, J.S., Damen, C.W., van Waterschoot, R.A., Iusuf, D., Beijnen, J.H., Schinkel, A.H., P-glycoprotein, multidrug-resistance associated protein 2, Cyp3a, and carboxylesterase affect the oral availability and metabolism of vinorelbine. Mol. Pharmacol. 82 (2012), 636–644.
50. Lancaster, C.S., Sprowl, J.A., Walker, A.L., Hu, S., Gibson, A.A., Sparreboom, A., Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics. Mol. Cancer Ther. 12 (2013), 1537–1544.
51. Lee, H.H., Leake, B.F., Teft, W., Tirona, R.G., Kim, R.B., Ho, R.H., Contribution of hepatic organic anion-transporting polypeptides to docetaxel uptake and clearance. Mol. Cancer Ther. 14 (2015), 994–1003.
52. Lee, W., Glaeser, H., Smith, L.H., Roberts, R.L., Moeckel, G.W., Gervasini, G., Leake, B.F., Kim, R.B., Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J. Biol. Chem. 280 (2005), 9610–9617.
53. Leuthold, S., Hagenbuch, B., Mohebbi, N., Wagner, C.A., Meier, P.J., Stieger, B., Mechanisms of pH-gradient driven transport mediated by organic anion polypeptide transporters. Am. J. Physiol. Cell Physiol. 296 (2009), C570–C582.
54. Lu, H., Choudhuri, S., Ogura, K., Csanaky, I.L., Lei, X., Cheng, X., Song, P.Z., Klaassen, C.D., Characterization of organic anion transporting polypeptide 1b2-null mice: essential role in hepatic uptake/toxicity of phalloidin and microcystin-LR. Toxicol. Sci. 103 (2008), 35–45.
55. Martinez-Becerra, P., Briz, O., Romero, M.R., Macias, R.I., Perez, M.J., Sancho-Mateo, C., Lostao, M.P., Fernandez-Abalos, J.M., Marin, J.J., Further characterization of the electrogenicity and pH sensitivity of the human organic anion-transporting polypeptides OATP1B1 and OATP1B3. Mol. Pharmacol. 79 (2011), 596–607.
56. Mathijssen, R.H., Loos, W.J., Verweij, J., Sparreboom, A., Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr. Cancer Drug Targets 2 (2002), 103–123.
57. Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., Gianni, L., Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56 (2004), 185–229.
58. Monks, N.R., Liu, S., Xu, Y., Yu, H., Bendelow, A.S., Moscow, J.A., Potent cytotoxicity of the phosphatase inhibitor microcystin LR and microcystin analogues in OATP1B1- and OATP1B3-expressing HeLa cells. Mol. Cancer Ther. 6 (2007), 587–598.
59. Muto, M., Onogawa, T., Suzuki, T., Ishida, T., Rikiyama, T., Katayose, Y., Ohuchi, N., Sasano, H., Abe, T., Unno, M., Human liver-specific organic anion transporter-2 is a potent prognostic factor for human breast carcinoma. Cancer Sci. 98 (2007), 1570–1576.
60. Nakanishi, T., Tamai, I., Genetic polymorphisms of OATP transporters and their impact on intestinal absorption and hepatic disposition of drugs. Drug Metab. Pharmacokinet. 27 (2012), 106–121.
61. Nakanishi, T., Tamai, I., Putative roles of organic anion transporting polypeptides (OATPs) in cell survival and progression of human cancers. Biopharm. Drug Dispos. 35 (2014), 463–484.
62. Niemi, M., Pasanen, M.K., Neuvonen, P.J., Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol. Rev. 63 (2011), 157–181.
63. Nieuweboer, A.J., Hu, S., Gui, C., Hagenbuch, B., Ghobadi Moghaddam-Helmantel, I.M., Gibson, A.A., de Bruijn, P., Mathijssen, R.H., Sparreboom, A., Influence of drug formulation on OATP1B-mediated transport of paclitaxel. Cancer Res. 74 (2014), 3137–3145.
64. Nozawa, T., Minami, H., Sugiura, S., Tsuji, A., Tamai, I., Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab. Dispos. 33 (2005), 434–439.
65. Obaidat, A., Roth, M., Hagenbuch, B., The expression and function of organic anion transporting polypeptides in normal tissues and in cancer. Annu. Rev. Pharmacol. Toxicol. 52 (2012), 135–151.
66. Ohnishi, S., Hays, A., Hagenbuch, B., Cysteine scanning mutagenesis of transmembrane domain 10 in organic anion transporting polypeptide 1B1. Biochemistry 53 (2014), 2261–2270.
67. Okabe, M., Unno, M., Harigae, H., Kaku, M., Okitsu, Y., Sasaki, T., Mizoi, T., Shiiba, K., Takanaga, H., Terasaki, T., Matsuno, S., Sasaki, I., Ito, S., Abe, T., Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem. Biophys. Res. Commun. 333 (2005), 754–762.
68. Oostendorp, R.L., van de Steeg, E., van der Kruijssen, C.M., Beijnen, J.H., Kenworthy, K.E., Schinkel, A.H., Schellens, J.H., Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors. Drug Metab. Dispos. 37 (2009), 917–923.
69. Ose, A., Kusuhara, H., Endo, C., Tohyama, K., Miyajima, M., Kitamura, S., Sugiyama, Y., Functional characterization of mouse organic anion transporting peptide 1a4 in the uptake and efflux of drugs across the blood-brain barrier. Drug Metab. Dispos. 38 (2010), 168–176.
70. Paller, C.J., Antonarakis, E.S., Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des. Dev. Ther. 5 (2011), 117–124.
71. Roth, M., Araya, J.J., Timmermann, B.N., Hagenbuch, B., Isolation of modulators of the liver-specific organic anion-transporting polypeptides (OATPs) 1B1 and 1B3 from Rollinia emarginata Schlecht (Annonaceae). J. Pharmacol. Exp. Ther. 339 (2011), 624–632.
72. Rowinsky, E.K., Donehower, R.C., Paclitaxel (taxol). N. Engl. J. Med. 332 (1995), 1004–1014.
73. Salphati, L., Chu, X., Chen, L., Prasad, B., Dallas, S., Evers, R., Mamaril-Fishman, D., Geier, E.G., Kehler, J., Kunta, J., Mezler, M., Laplanche, L., Pang, J., Rode, A., Soars, M.G., Unadkat, J.D., van Waterschoot, R.A., Yabut, J., Schinkel, A.H., Scheer, N., Evaluation of organic anion transporting polypeptide 1B1 and 1B3 humanized mice as a translational model to study the pharmacokinetics of statins. Drug Metab. Dispos. 42 (2014), 1301–1313.
74. Sasaki, M., Suzuki, H., Aoki, J., Ito, K., Meier, P.J., Sugiyama, Y., Prediction of in vivo biliary clearance from the in vitro transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II monolayer expressing both rat organic anion transporting polypeptide 4 and multidrug resistance associated protein 2. Mol. Pharmacol. 66 (2004), 450–459.
75. Shapiro, A.B., Ling, V., The mechanism of ATP-dependent multidrug transport by P-glycoprotein. Acta Physiol. Scand. Suppl. 643 (1998), 227–234.
76. Shitara, Y., Maeda, K., Ikejiri, K., Yoshida, K., Horie, T., Sugiyama, Y., Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm. Drug Dispos. 34 (2013), 45–78.
77. Sissung, T.M., Reece, K.M., Spencer, S., Figg, W.D., Contribution of the OATP1B subfamily to cancer biology and treatment. Clin. Pharmacol. Ther. 92 (2012), 658–660.
78. Smith, N.F., Figg, W.D., Sparreboom, A., Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol. In Vitro 20 (2006), 163–175.
79. Sparreboom, A., Mathijssen, R.H., Hepatic uptake transporters and docetaxel disposition in mice-letter. Clin. Cancer Res., 20, 2014, p4167.
80. Sprowl, J.A., Sparreboom, A., Uptake carriers and oncology drug safety. Drug Metab. Dispos. 42 (2014), 611–622.
81. Stangier, J., Su, C.A., Roth, W., Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J. Int. Med. Res. 28 (2000), 149–167.
82. Stieger, B., Hagenbuch, B., Organic anion-transporting polypeptides. Curr. Top. Membr. 73 (2014), 205–232.
83. Svoboda, M., Wlcek, K., Taferner, B., Hering, S., Stieger, B., Tong, D., Zeillinger, R., Thalhammer, T., Jager, W., Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: relevance for paclitaxel transport. Biomed. Pharmacother. 65 (2011), 417–426.
84. Takane, H., Kawamoto, K., Sasaki, T., Moriki, K., Moriki, K., Kitano, H., Higuchi, S., Otsubo, K., Ieiri, I., Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy. Cancer Chemother. Pharmacol. 63 (2009), 1165–1169.
85. Tang, S.C., Hendrikx, J.J., Beijnen, J.H., Schinkel, A.H., Genetically modified mouse models for oral drug absorption and disposition. Curr. Opin. Pharmacol. 13 (2013), 853–858.
86. Tang, S.C., Kort, A., Cheung, K.L., Rosing, H., Fukami, T., Durmus, S., Wagenaar, E., Hendrikx, J.J., Nakajima, M., van Vlijmen, B.J., Beijnen, J.H., Schinkel, A.H., P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain disposition and oral availability of the novel taxane cabazitaxel (jevtana) in mice. Mol. Pharm. 12 (2015), 3714–3723.
87. Tang, S.C., Sparidans, R.W., Cheung, K.L., Fukami, T., Durmus, S., Wagenaar, E., Yokoi, T., van Vlijmen, B.J., Beijnen, J.H., Schinkel, A.H., P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR Inhibitor everolimus (Afinitor) in mice. Clin. Cancer Res. 20 (2014), 3133–3145.
88. Thakkar, N., Lockhart, A.C., Lee, W., Role of organic anion-transporting polypeptides (OATPs) in cancer therapy. AAPS J. 17 (2015), 535–545.
89. Trevino, L.R., Shimasaki, N., Yang, W., Panetta, J.C., Cheng, C., Pei, D., Chan, D., Sparreboom, A., Giacomini, K.M., Pui, C.H., Evans, W.E., Relling, M.V., Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J. Clin. Oncol. 27 (2009), 5972–5978.
90. van de Steeg, E., Stranecky, V., Hartmannova, H., Noskova, L., Hrebicek, M., Wagenaar, E., van Esch, A., de Waart, D.R., Oude Elferink, R.P., Kenworthy, K.E., Sticova, E., al-Edreesi, M., Knisely, A.S., Kmoch, S., Jirsa, M., Schinkel, A.H., Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J. Clin. Invest. 122 (2012), 519–528.
91. van de Steeg, E., van der Kruijssen, C.M., Wagenaar, E., Burggraaff, J.E., Mesman, E., Kenworthy, K.E., Schinkel, A.H., Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1). Drug Metab. Dispos. 37 (2009), 277–281.
92. van de Steeg, E., van Esch, A., Wagenaar, E., Kenworthy, K.E., Schinkel, A.H., Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice. Clin. Cancer Res. 19 (2013), 821–832.
93. Van de Steeg, E., van Esch, A., Wagenaar, E., van der Kruijssen, C.M., van Tellingen, O., Kenworthy, K.E., Schinkel, A.H., High impact of Oatp1a/1b transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel. Clin. Cancer Res. 17 (2011), 294–301.
94. van de Steeg, E., Wagenaar, E., van der Kruijssen, C.M., Burggraaff, J.E., de Waart, D.R., Elferink, R.P., Kenworthy, K.E., Schinkel, A.H., Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. J. Clin. Invest. 120 (2010), 2942–2952.
95. van Outryve, S., Schrijvers, D., van den Brande, J., Wilmes, P., Bogers, J., van Marck, E., Vermorken, J.B., Methotrexate-associated liver toxicity in a patient with breast cancer: case report and literature review. Neth. J. Med. 60 (2002), 216–222.
96. Vasilyeva, A., Durmus, S., Li, L., Wagenaar, E., Hu, S., Gibson, A.A., Panetta, J.C., Mani, S., Sparreboom, A., Baker, S.D., Schinkel, A.H., Hepatocellular shuttling and recirculation of sorafenib-glucuronide is dependent on Abcc2, Abcc3, and Oatp1a/1b. Cancer Res. 75 (2015), 2729–2736.
97. Watanabe, T., Kusuhara, H., Maeda, K., Shitara, Y., Sugiyama, Y., Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J. Pharmacol. Exp. Ther. 328 (2009), 652–662.
98. Watanabe, T., Kusuhara, H., Sugiyama, Y., Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans. J. Pharmacokinet. Pharmacodyn. 37 (2010), 575–590.
99. Wessels, J.A., Huizinga, T.W., Guchelaar, H.J., Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxf.) 47 (2008), 249–255.
100. Wu, P., Nielsen, T.E., Clausen, M.H., FDA-approved small-molecule kinase inhibitors. Trends Pharmacol. Sci. 36 (2015), 422–439.
101. Xiang, X., Jada, S.R., Li, H.H., Fan, L., Tham, L.S., Wong, C.I., Lee, S.C., Lim, R., Zhou, Q.Y., Goh, B.C., Tan, E.H., Chowbay, B., Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients. Pharmacogenet. Genomics 16 (2006), 683–691.
102. Yamaguchi, H., Kobayashi, M., Okada, M., Takeuchi, T., Unno, M., Abe, T., Goto, J., Hishinuma, T., Mano, N., Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. Cancer Lett. 260 (2008), 163–169.
103. Zaher, H., Meyer zu Schwabedissen, H.E., Tirona, R.G., Cox, M.L., Obert, L.A., Agrawal, N., Palandra, J., Stock, J.L., Kim, R.B., Ware, J.A., Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin. Mol. Pharmacol. 74 (2008), 320–329.
104. Zelcer, N., Huisman, M.T., Reid, G., Wielinga, P., Breedveld, P., Kuil, A., Knipscheer, P., Schellens, J.H., Schinkel, A.H., Borst, P., Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J. Biol. Chem. 278 (2003), 23538–23544.
105. Zhou, S., Chan, E., Duan, W., Huang, M., Chen, Y.Z., Drug bioactivation, covalent binding to target proteins and toxicity relevance. Drug Metab. Rev. 37 (2005), 41–213.
106. Zimmerman, E.I., Hu, S., Roberts, J.L., Gibson, A.A., Orwick, S.J., Li, L., Sparreboom, A., Baker, S.D., Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin. Cancer Res. 19 (2013), 1458–1466.